Hereditary non-polyposis colorectal cancer (HNPCC) is associated with germline mutations in the DNA mismatch repair gene hMSH2 [1], the human homologue of the Escherichia coli MutS gene. These are mostly nonsense, frameshift or deletion mutations that result in loss of intact protein and complete inactivation of DNA mismatch repair. However, cancer is also associated with hMSH2 missense mutations that are merely inferred to be deleterious because they result in non-conservative substitutions of amino acids that are highly conserved among MutS family proteins. Moreover, sequence polymorphisms exist in hMSH2 that also change conserved amino acids but whose functional consequences and relationship to cancer are uncertain. Here, we show that yeast strains harboring putative equivalents of three hMSH2 polymorphisms have elevated mutation rates. Mutator effects were also observed for yeast equivalents of hMSH2 missense mutations found in HNPCC families and in an early onset colon tumor. Several distinct phenotypes were observed, indicating that these missense mutations have differential effects on MSH2 function(s). The results suggest that cancer may be associated with even partial loss of hMSH2 function and they are consistent with the hypothesis that polymorphisms in hMSH2 might predispose humans to disease. Results and discussion Table 1 lists seven hMSH2 missense mutations that change conserved amino acids in hMSH2, the last six of which have unknown functional consequences. We examined their effects on mutation rates in two yeast model systems. One system [2] examines the ability of yeast MSH2 (yMSH2) mutant alleles homologous to the human mutations (Figure 1 ) to reduce the high mutation rate of a msh2 -yeast strain or to elevate the low mutation rate of a wild-type strain. The other system [3] examines the dominant mutator effect produced by coexpression of wild-type hMSH2 and hMSH6 in wild-type yeast, thought to result from formation of a human MutSα complex that binds to and prevents correction of replication errors.
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We first examined missense mutations anticipated to inactivate mismatch repair because of their known association with HNPCC [1] . For example, an R524P mutation (using single-letter amino acid code) in hMSH2 has been found in an ovarian tumor of an HNPCC patient [4] . A cell line derived from this tumor exhibits microsatellite instability [4, 5] and is defective in mismatch-repair activity [6] . When the homologous R542P mutation in yMSH2 was expressed from the GAL10 promoter in a 2µ plasmid in a msh2 strain (all MSH2p mutants were expressed as confirmed by immunoblot analysis), it did not reduce the high rate of single-base deletions at an (A) 14 run in the LYS2 gene or the rate of forward mutations at the canavanine (CAN) locus (Table 2 ). In contrast, expression of the wildtype yMSH2 gene from the GAL10 promoter or from the MSH2 promoter in an ARS-CEN plasmid reduced the mutation rate at both loci [2] (Table 2) . For hMSH2, coexpression of wild-type hMSH2p (from a GAL10 promoter) with hMSH6p (from a GAL1 promoter) in wild-type yeast elevated the mutation rate by 3,900-fold (Table 3 ). In contrast, coexpression of hMSH2p(R524P) with hMSH6p had no effect on the mutation rate [3] (Table 3) . Consistent with loss of the dominant mutator effect, extracts of cells coexpressing hMSH2p(R524P) with hMSH6p do not yield a band shift with a mismatched oligonucleotide [3] ; a similar loss of band shift capacity was observed with the homologous yeast proteins (data not shown). The data from the two assays are consistent with results with the human tumor cell line [4] [5] [6] and suggest that the arginine to proline mutation in both yeast and human MSH2 strongly inactivates mismatch repair.
Yeast carrying the msh2 missense mutations P640L [7] and C716F [8] (Table 1, Figure 1 ), which are homologous to the HNPCC msh2 mutations P622L and C697F, respectively, also failed to fully complement a msh2 strain (Table 2) , suggesting inactivation of mismatch repair. As for R524P, the human P622L mutant abolished the dominant mutator effect (Table 3 ) and ability to cause a band shift (data not shown, but for example, see Figure 3 in [3] ). Thus, these mutants might confer a defect in MutSα heterodimer formation and/or nucleic-acid binding, perhaps resulting from a change in protein conformation due to non-conservative substitutions involving proline.
The mutation rates seen when the yeast homologues of the three HNPCC mutants were expressed from the GAL10 promoter were lower than when expressed from the MSH2 promoter ( Table 2 ), suggesting that repair was not completely abolished. These expression-related differences in rates were not the same for the three mutants, which also differed in ability to confer a dominant mutator effect at the LYS2 locus when expressed in wild-type yeast (Table 2) . Thus, although these missense mutations clearly affected mismatch repair function, their phenotypes were distinct.
We next examined an MSH2 missense mutation (D506Y) found in the germ line of a Korean patient with early onset colon cancer [9] . The homologous D524Y mutant in yMSH2 was partially defective in complementing the mutator phenotype of a msh2 strain (Table 2 ; for example, a 72-fold effect at the (A) 14 run). However, as shown in Table 2 , it retained some mismatch repair function as evidenced by its ability to reduce the mutator phenotype of the msh2 strain when overexpressed (310-fold at the LYS2 locus; compare 620 × 10 -6 with 2 × 10 -6 ; and 24-fold at the CAN locus). Moreover, coexpression of hMSH2p(D506Y) with hMSH6p yielded a 4,600-fold dominant mutator phenotype in a wild-type yeast strain (Table 3 ) and a cell extract that retained the ability to cause a band shift (data not shown), suggesting that the D506Y mutant interacts with hMSH6p and that the mutant MutSα complex binds This suggestion prompted an analysis of missense mutations that replace conserved amino acids in hMSH2 and that are common variant alleles in humans. An example is the non-conservative substitution of aspartic acid for Gly322, resulting from a glycine→alanine nucleotide transition. This allele has been detected at a 1-6% frequency in studies of patients with sporadic colorectal cancer and unaffected controls [8, [10] [11] [12] [13] [14] [15] [16] , and has also been found in a family which fulfilled the Amsterdam criteria for HNPCC [17] . Thus, the G322D allele is common and has been considered a sequence variant unrelated to cancer, a possible low-penetrance allele, or a mutation predisposing to HNPCC. Yeast carrying the putative equivalent mutation G317D (Figure 1 ) partially complemented the mutator defect at the LYS2 or CAN locus in a msh2 strain when expressed from the GAL10 promoter (Table 2 ). Complementation was ineffective, however, when expressed from the yMSH2 promoter, suggesting that the G317D msh2 mutation partially inactivates mismatch repair. When the human G322D msh2 mutant was expressed with hMSH6p in yeast, it produced a dominant mutator effect (Table 3) and a band shift similar to that observed with the wildtype MSH2p (data not shown). These results suggest that hmsh2p (G322D) interacts with hMSH6p and that the complex binds to mismatches. Thus, a defect in mismatch repair suggested by results with the putative homologous yeast mutant could reflect events in the repair pathway that are downstream of these interactions (for example, a defect in other protein-protein or substrate interactions) or required for a protein conformational change. An important caveat is that the alignments in Figure 1 are insufficient to establish unequivocally that Gly317 in yMSH2 is functionally equivalent to Gly322 in hMSH2.
Two other missense alleles whose functional consequences have not been reported are Q419K and L390F Table 2 Effect of expression of MSH2 mutants on mutation rates of msh2 and MSH2 yeast strains. All mutation rates are × 10 6 and should be compared with the rates shown for the equivalent wild-type MSH2 (see third row). Rates and 95% confidence limits (data not shown) were calculated, as described in [3] , from multiple (typically 12) independent determinations. Foldincrease over the wild-type rate is indicated within the brackets. ND, not determined. *These rates are higher than in the wild-type (non-overlapping confidence intervals). † These mutants carry a sequence encoding the His 6 epitope tag at the 5′ end of the gene. ‡ Although this value was not determined, it can be assumed that both vector constructs without the MSH2 gene result in the same mutation rate, as all cultures were grown in the same media. ( Table 1 ). The Q419K mutation was identified in a colon cancer patient, but it was not implicated in the cancer and was described as a polymorphism [18] . The L390F mutation has also been found in colon cancer patients and is viewed as a possible HNPCC mutation [19] or as a polymorphism [18, 19] . Yeast carrying the putative equivalent mutations, Q430K and L402F, yield significant mutator effects (Table 2) , indicating a functional defect. Some function is retained though, because when expressed from the yMSH2 promoter, the Q430K and L402F mutants reduced the mutator defect at the LYS2 or CAN locus in a msh2 strain by more than 10-fold (Table 2) . Unexpectedly, when expressed from the GAL10 promoter, the Q430K and L402F mutants were actually less efficient in complementing the mutator phenotype, a result opposite to that seen with the other missense mutants. Expression of the Q430K and L402F mutants from either plasmid did not confer a dominant mutator effect to a wild-type yeast strain (Table 2 ). When the human L390F and Q419K msh2 mutants were expressed with hMSH6p, they produced dominant mutator effects (Table 3 ) and band shifts like those observed with wildtype MSH2p (data not shown).
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These data suggest that mismatch repair defects are conferred by seven different msh2 missense mutations, several of which are homologous to mutations in hMSH2 that have been implicated in cancer and three of which might be common in the normal human population. The phenotypes of the msh2 mutations were complex, suggesting that the mutations alter MSH2p function in different ways. Because the alignments in Figure 1 do not by themselves establish functional equivalence, and as there are obvious differences between yeast and human cells, additional functional and population-based studies in humans will be required to determine whether these hMSH2 polymorphisms are clinically relevant. Nonetheless, the defects reported here with the yeast G317D, L402F and Q430K mutants are consistent with the hypothesis that common polymorphisms in hMSH2 may predispose humans to disease.
Materials and methods

Strains, plasmids, genetic and biochemical methods
All strains, plasmids and methods used in this work have been described previously [2, 3] .
